

HARRIS & HARRIS GROUP INC /NY/
Form 10-Q
May 10, 2010

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2010

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 0-11576

HARRIS & HARRIS GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)

New York (State or Other Jurisdiction of Incorporation or Organization)	13-3119827 (I.R.S. Employer Identification No.)
1450 Broadway, New York, New York (Address of Principal Executive Offices)	10018 (Zip Code)

(212) 582-0900

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: HARRIS & HARRIS GROUP INC /NY/ - Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at May 10, 2010
Common Stock, \$0.01 par value per share	30,864,899 shares

Harris & Harris Group, Inc.
Form 10-Q, March 31, 2010

Page Number

PART I. FINANCIAL INFORMATION	
Item 1. Consolidated Financial Statements	1
Consolidated Statements of Assets and Liabilities	2
Consolidated Statements of Operations	3
Consolidated Statements of Cash Flows	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Schedule of Investments	6
Notes to Consolidated Financial Statements	33
Financial Highlights	42
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	43
Background and Overview	43
Historical Investments	44
Investment Pace	44
Importance of Availability of Liquid Capital	46
Involvement with Portfolio Companies	48
Commercialization of Nanotechnology by Our Portfolio Companies	48
Maturity of Current Venture Capital Portfolio	51
Current Business Environment	53
Valuation of Investments	54
Investment Objective	57
Results of Operations	58
Financial Condition	61
Liquidity	63
Capital Resources	63
Critical Accounting Policies	64
Recent Developments – Portfolio Companies	66
Forward-Looking Statements	67
Item 3. Quantitative and Qualitative Disclosures About Market Risk	67

Item 4. Controls and Procedures	69
---------------------------------	----

PART II. OTHER INFORMATION

Item 1A. Risk Factors	70
-----------------------	----

Item 5. Exhibits	71
------------------	----

Signatures	72
------------	----

Exhibit Index	73
---------------	----

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

The information furnished in the accompanying consolidated financial statements reflects all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim period presented.

Harris & Harris Group, Inc.® (the "Company," "us," "our" and "we"), is an internally managed venture capital company that has elected to operate as a business development company ("BDC") under the Investment Company Act of 1940 (the "1940 Act"). Certain information and disclosures normally included in the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted as permitted by Regulation S-X and Regulation S-K. The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2009, contained in our Annual Report on Form 10-K for the year ended December 31, 2009.

In September 1997, our Board of Directors approved a proposal to seek qualification as a regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code (the "Code"). At that time, we were taxable under Subchapter C of the Code (a "C Corporation"). We filed for the 1999 tax year to elect treatment as a RIC. In order to qualify as a RIC, we must, in general, (1) annually, derive at least 90 percent of our gross income from dividends, interest, gains from the sale of securities and similar sources; (2) quarterly, meet certain investment diversification requirements; and (3) annually, distribute at least 90 percent of our investment company taxable income as a dividend. In addition to the requirement that we must annually distribute at least 90 percent of our investment company taxable income, we may either distribute or retain our net capital gain from investments, but any net capital gain not distributed will be subject to corporate income tax and the excise tax described below. We will be subject to a four percent excise tax to the extent we fail to distribute at least 98 percent of our annual net ordinary income and 98 percent of our capital gain net income and would be subject to income tax to the extent we fail to distribute 100 percent of our investment company taxable income.

Because of the specialized nature of our investment portfolio, we generally can satisfy the diversification requirements under Subchapter M of the Code if we receive a certification from the Securities and Exchange Commission ("SEC") that we are "principally engaged in the furnishing of capital to other corporations which are principally engaged in the development or exploitation of inventions, technological improvements, new processes, or products not previously generally available."

On June 9, 2009, we received SEC certification for 2008, permitting us to qualify for RIC treatment for 2008 (as we had for the years 1999 through 2007) pursuant to Section 851(e) of the Code. Although the SEC certification for 2008 was issued, there can be no assurance that we will qualify for or receive such certification for subsequent years (to the extent we need additional certification as a result of changes in our portfolio) or that we will actually qualify for Subchapter M treatment in subsequent years. On April 23, 2010, we applied for SEC certification for 2009. We qualified for RIC treatment in 2009 even without certification. In addition, under certain circumstances, even if we qualified for Subchapter M treatment in a given year, we might take action in a subsequent year to ensure that we would be taxed in that subsequent year as a C Corporation, rather than as a RIC. Because Subchapter M does not permit deduction of operating expenses against net capital gain, it is not clear that the Company and its shareholders have paid less in taxes since 1999 than they would have paid had the Company remained a C Corporation.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES

ASSETS

	March 31, 2010 (Unaudited)	December 31, 2009
Investments, in portfolio securities at value:		
Unaffiliated privately held companies (cost: \$31,002,395 and \$26,977,200, respectively)	\$ 29,752,075	\$ 21,656,436
Unaffiliated publicly traded securities (cost: \$547,304 and \$298,827, respectively)	552,454	226,395
Non-controlled affiliated privately held companies (cost: \$51,546,166 and \$54,864,948, respectively)	45,559,645	50,297,220
Controlled affiliated privately held companies (cost: \$11,032,574 and \$10,248,932, respectively)	7,703,226	5,843,430
Total, investments in privately held and publicly traded securities at value (cost: \$94,128,439 and \$92,389,907, respectively)	\$ 83,567,400	\$ 78,023,481
Investments, in U.S. Treasury obligations at value (cost: \$53,163,696 and \$55,960,024, respectively)	53,160,430	55,947,581
Cash	197,294	1,611,465
Restricted funds	2,000	2,000
Receivable from portfolio company	0	28,247
Interest receivable	6	25,832
Prepaid expenses	338,542	94,129
Receivable from unsettled trade	799,925	0
Other assets	691,853	376,366
Total assets	\$ 138,757,450	\$ 136,109,101

LIABILITIES & NET ASSETS

Post retirement plan liabilities	\$ 1,402,894	\$ 1,369,843
Accounts payable and accrued liabilities	672,902	579,162
Deferred rent	321,372	1,838
Total liabilities	2,397,168	1,950,843
Net assets	\$ 136,360,282	\$ 134,158,258
Net assets are comprised of:		
Preferred stock, \$0.10 par value, 2,000,000 shares authorized; none issued	\$ 0	\$ 0
Common stock, \$0.01 par value, 45,000,000 shares authorized at 03/31/10 and 12/31/09; 32,690,986 issued at 03/31/10 and 32,688,333 issued at 12/31/09	326,911	326,884
Additional paid in capital (Note 8)	206,491,383	205,977,117
Accumulated net operating and realized loss	(56,488,176)	(54,361,343)

Accumulated unrealized depreciation of investments	(10,564,305)	(14,378,869)
Treasury stock, at cost (1,828,740 shares at 03/31/10 and 12/31/09)	(3,405,531)	(3,405,531)
Net assets	\$ 136,360,282	\$ 134,158,258
Shares outstanding	30,862,246	30,859,593
Net asset value per outstanding share	\$ 4.42	\$ 4.35

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Three Months Ended March 31, 2010	Three Months Ended March 31, 2009
Investment income:		
Interest from:		
Fixed-income securities and bridge notes (Note 3)	\$ 73,073	\$ (35,899)
Miscellaneous income	6,000	12,338
Total investment income (loss)	79,073	(23,561)
Expenses:		
Salaries, benefits and stock-based compensation (Note 6)	1,389,277	1,387,340
Administration and operations	282,522	290,435
Professional fees	243,369	215,250
Rent (Note 3)	77,215	78,063
Directors' fees and expenses	95,361	84,509
Depreciation	11,969	12,859
Custody fees	24,000	6,862
Lease termination costs (Note 3)	68,038	0
Total expenses	2,191,751	2,075,318
Net operating loss	(2,112,678)	(2,098,879)
Net realized loss:		
Realized loss from investments:		
Unaffiliated companies	0	(3,288)
Non-controlled affiliated companies	0	0
Controlled affiliated companies	0	0
U.S. Treasury obligations/other	(11,523)	(325)
Realized loss from investments	(11,523)	(3,613)
Income tax expense (Note 7)	2,632	380
Net realized loss	(14,155)	(3,993)
Net decrease in unrealized depreciation on investments:		
Change on investments held	3,814,564	1,151,448
Net decrease in unrealized depreciation on investments	3,814,564	1,151,448
Net increase (decrease) in net assets resulting from operations:		
Total	\$ 1,687,731	\$ (951,424)

Per average basic and diluted outstanding share	\$	0.05	\$	(0.04)
Average outstanding shares		30,859,888		25,859,573

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three Months Ended March 31, 2010	Three Months Ended March 31, 2009
Cash flows (used in) provided by operating activities:		
Net increase (decrease) in net assets resulting from operations	\$ 1,687,731	\$ (951,424)
Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities:		
Net realized and unrealized (gain) on investments	(3,803,041)	(1,147,835)
Depreciation of fixed assets, amortization of premium or discount on U.S. government securities, and bridge note interest	(41,107)	86,269
Stock-based compensation expense	553,272	635,638
Changes in assets and liabilities:		
Restricted funds	0	(618)
Receivable from portfolio company	28,247	0
Interest receivable	12,589	54,660
Receivable from investments sold	(799,925)	0
Prepaid expenses	(244,413)	137,680
Other assets	(260,892)	3,312
Post retirement plan liabilities	33,051	30,981
Accounts payable and accrued liabilities	93,740	(131,084)
Deferred rent	319,534	(1,576)
Net cash used in operating activities	(2,421,214)	(1,283,997)
Cash flows from investing activities:		
Purchase of U.S. government securities	(2,399,293)	(52,334,768)
Sale of U.S. government securities	5,199,533	53,892,347
Investment in venture capital investments	(1,675,058)	(723,176)
Proceeds from conversion of bridge note	1,356	0
Purchase of fixed assets	(80,516)	(1,313)
Net cash provided by investing activities	1,046,022	833,090
Cash flows from financing activities:		
Proceeds from stock option exercises	9,949	0
Payment of offering costs	(48,928)	0
Net cash used in financing activities	(38,979)	0
Net decrease in cash:		

Edgar Filing: HARRIS & HARRIS GROUP INC /NY/ - Form 10-Q

Cash at beginning of the period	1,611,465	692,309
Cash at end of the period	197,294	241,402
Net decrease in cash	\$ (1,414,171)	\$ (450,907)
Supplemental disclosures of cash flow information:		
Income taxes paid	\$ 2,632	\$ 380

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS

	Three Months Ended March 31, 2010 (Unaudited)	Year Ended December 31, 2009
Changes in net assets from operations:		
Net operating loss	\$ (2,112,678)	\$ (8,761,215)
Net realized loss on investments	(14,155)	(11,105,577)
Net decrease in unrealized depreciation on investments as a result of sales	0	11,090,579
Net decrease in unrealized depreciation on investments held	3,814,564	8,627,748
Net increase (decrease) in net assets resulting from operations	1,687,731	(148,465)
Changes in net assets from capital stock transactions:		
Issuance of common stock upon the exercise of stock options	27	1,125
Issuance of common stock on offering	0	48,875
Additional paid-in capital on common stock issued and options exercised	(39,006)	21,636,090
Stock-based compensation expense	553,272	3,089,520
Net increase in net assets resulting from capital stock transactions	514,293	24,775,610
Net increase in net assets	2,202,024	24,627,145
Net assets:		
Beginning of the period	134,158,258	109,531,113
End of the period	\$ 136,360,282	\$ 134,158,258

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 22.2% of net assets at value			
Private Placement Portfolio (Illiquid) – 21.8% of net assets at value			
BioVex Group, Inc. (5)(6)(7)(8) -- Developing novel biologics for treatment of cancer and infectious disease			
Series E Convertible Preferred Stock	(M)	2,799,552	\$ 1,042,862
Series G Convertible Preferred Stock	(M)	3,738,004	627,985
Warrants at \$0.21 expiring 11/5/16	(I)	285,427	18,838
			1,689,685
Bridgelux, Inc. (5)(6) -- Manufacturing high-power light emitting diodes (LEDs) and arrays			
Series B Convertible Preferred Stock	(M)	1,861,504	2,345,495
Series C Convertible Preferred Stock	(M)	2,130,699	2,684,681
Series D Convertible Preferred Stock	(M)	999,999	1,259,999
Warrants at \$0.7136 expiring 12/31/14	(I)	163,900	135,218
Warrants at \$1.50 expiring 8/26/14	(I)	166,665	101,332
			6,526,725
Cobalt Technologies, Inc. (5)(6)(7)(9) -- Developing processes for making biobutanol through biomass fermentation			
Series C Convertible Preferred Stock	(M)	352,112	375,000
D-Wave Systems, Inc. (5)(6)(7)(10) -- Developing high- performance quantum computing systems			
Series B Convertible Preferred Stock	(M)	1,144,869	938,620
Series C Convertible Preferred Stock	(M)	450,450	369,301

Series D Convertible Preferred Stock	(M)	1,533,395	1,257,153
			2,565,074
Molecular Imprints, Inc. (5)(6) -- Manufacturing nanoimprint lithography capital equipment			
Series B Convertible Preferred Stock	(M)	1,333,333	2,999,999
Series C Convertible Preferred Stock	(M)	1,250,000	2,812,500
Warrants at \$2.00 expiring 12/31/11	(I)	125,000	155,375
			5,967,874

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 22.2% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 21.8% of net assets at value (Cont.)			
Nanosys, Inc. (5)(6) -- Developing inorganic materials and devices based on nanowires and quantum dots			
Series C Convertible Preferred Stock	(M)	803,428	\$ 1,185,056
Series D Convertible Preferred Stock	(M)	1,016,950	1,500,001
			2,685,057
Nantero, Inc. (5)(6)(7) -- Developing a high-density, nonvolatile, random access memory chip, enabled by carbon nanotubes			
Series A Convertible Preferred Stock	(M)	345,070	1,046,908
Series B Convertible Preferred Stock	(M)	207,051	628,172
Series C Convertible Preferred Stock	(M)	188,315	571,329
			2,246,409
NeoPhotonics Corporation (5)(6) -- Developing and manufacturing optical devices and components			
Common Stock	(M)	1,130,440	1,030,961
Series 1 Convertible Preferred Stock	(M)	1,831,256	1,670,105
Series 2 Convertible Preferred Stock	(M)	741,898	676,611
Series 3 Convertible Preferred Stock	(M)	2,750,000	2,508,000
Series X Convertible Preferred Stock	(M)	8,923	1,427,680
			7,313,357
Polatis, Inc. (5)(6)(7) -- Developing MEMS-based optical networking components			
Series A-1 Convertible Preferred Stock	(M)	16,775	0
Series A-2 Convertible Preferred Stock	(M)	71,611	0
Series A-4 Convertible Preferred Stock	(M)	4,774	0

Series A-5 Convertible Preferred Stock	(M)	16,438	0
			0
PolyRemedy, Inc. (5)(6)(7) -- Developing a robotic manufacturing platform for wound treatment patches			
Series B-1 Convertible Preferred Stock	(M)	287,647	23,467
Series B-2 Convertible Preferred Stock	(M)	676,147	30,427
			53,894

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 22.2% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 21.8% of net assets at value (Cont.)			
Siluria Technologies, Inc. (5)(6)(7) -- Developing nanomaterials for manufacturing of chemicals			
Series S-2 Convertible Preferred Stock	(M)	612,061	\$ 204,000
TetraVitae Bioscience, Inc. (5)(6)(7)(11) -- Developing methods of producing alternative chemicals and fuels through biomass fermentation			
Series B Convertible Preferred Stock	(M)	118,804	125,000
Total Unaffiliated Private Placement Portfolio (cost: \$31,002,395)			
		\$	29,752,075

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Publicly Traded Portfolio – 0.4% of net assets at value			
Orthovita, Inc. (6) -- Developing materials and devices for orthopedic medical implant applications			
Common Stock	(M)	93,100	\$ 396,606
Satcon Technology Corporation (6)(12) – Developing power conversion solutions and providing system design services for utility-scale renewable energy plants			
Common Stock	(M)	64,400	155,848
Total Unaffiliated Publicly Traded Portfolio (cost: \$547,304)			\$ 552,454
Total Investments in Unaffiliated Companies (cost: \$31,549,699)			\$ 30,304,529

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Non-Controlled Affiliated Companies			
(2)(13) –			
33.4% of net assets at value			
Private Placement Portfolio (Illiquid) – 33.4% of net assets at value			
ABS Materials, Inc. (5)(6)(7)(12) -- Developing nano-structured materials for environmental remediation and the petroleum industry			
Series A Convertible Preferred Stock	(M)	250,000	\$ 250,000
Adesto Technologies Corporation (5)(6)(7) -- Developing low-power, high-performance memory devices			
Series A Convertible Preferred Stock	(M)	6,547,619	2,420,000
Series B Convertible Preferred Stock	(M)	5,952,381	2,200,000
			4,620,000
Cambrios Technologies Corporation (5)(6)(7) -- Developing nanowire-enabled electronic materials for the display industry			
Series B Convertible Preferred Stock	(M)	1,294,025	647,013
Series C Convertible Preferred Stock	(M)	1,300,000	650,000
Series D Convertible Preferred Stock	(M)	515,756	257,878
			1,554,891
Contour Energy Systems, Inc. (5)(6)(7)(14) -- Developing batteries using nanostructured materials			
Series A Convertible Preferred Stock	(M)	2,565,798	2,822,378
Series B Convertible Preferred Stock	(M)	812,500	1,300,000
			4,122,378
Crystal IS, Inc. (5)(6) -- Developing single-crystal			

aluminum nitride substrates for light-emitting diodes

Common Stock	(M)	3,994,468	0
Warrants at \$0.78 expiring 05/05/13	(I)	15,231	0
Warrants at \$0.78 expiring 05/12/13	(I)	2,350	0
Warrants at \$0.78 expiring 08/08/13	(I)	4,396	0
			0

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Non-Controlled Affiliated Companies			
(2)(13) – 33.4% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 33.4% of net assets at value (Cont.)			
Ensemble Discovery Corporation (5)(6)(15) -- Developing DNA- Programmed Chemistry™ for the discovery of new classes of therapeutics			
Series B Convertible Preferred Stock	(M)	1,449,275	\$ 2,000,000
Unsecured Convertible Bridge Note (including interest)	(M)	\$ 299,169	331,472
			2,331,472
Enumeral Technologies, Inc. (5)(6)(7) -- Developing therapeutics and diagnostics through functional assaying of single cells			
Unsecured Convertible Bridge Note (including interest)	(M)	\$ 250,000	255,425
Innovalight, Inc. (5)(6)(7) -- Developing solar power products enabled by silicon-based nanomaterials			
Series B Convertible Preferred Stock	(M)	16,666,666	2,969,667
Series C Convertible Preferred Stock	(M)	5,810,577	1,276,457
Series D Convertible Preferred Stock	(M)	4,046,974	721,090
			4,967,214
Kovio, Inc. (5)(6) -- Developing semiconductor products using printed electronics and thin-film technologies			
Series C Convertible Preferred Stock	(M)	2,500,000	640,313
Series D Convertible Preferred Stock	(M)	800,000	204,900
Series E Convertible Preferred Stock	(M)	1,200,000	307,350
Warrants at \$1.25 expiring 12/31/12	(I)	355,880	29,538
			1,182,101

Mersana Therapeutics, Inc. (5)(6)(7) -- Developing treatments for

cancer based on novel drug delivery polymers

Series A Convertible Preferred Stock	(M)		68,451	136,902
Series B Convertible Preferred Stock	(M)		866,500	1,733,000
Unsecured Convertible Bridge Note (including interest)	(M)	\$	821,975	899,020
Warrants at \$2.00 expiring 10/21/10	(I)		91,625	57,082
				2,826,004

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Non-Controlled Affiliated Companies (2)(13) – 33.4% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 33.4% of net assets at value (Cont.)			
Metabolon, Inc. (5)(6) -- Developing service and diagnostic products through the use of a metabolomics, or biochemical, profiling platform			
Series B Convertible Preferred Stock	(M)	371,739	\$ 1,087,870
Series B-1 Convertible Preferred Stock	(M)	148,696	435,149
Series C Convertible Preferred Stock	(M)	1,000,000	1,000,000
Warrants at \$1.15 expiring 3/25/15	(I)	74,348	112,921
			2,635,940
NanoGram Corporation (5)(6) -- Developing solar power products enabled by silicon-based nanomaterials			
Common Stock	(M)	2,988,437	0
			0
Nextreme Thermal Solutions, Inc. (5)(6) -- Developing thin-film thermoelectric devices for cooling and energy conversion			
Series A Convertible Preferred Stock	(M)	17,500	1,312,500
Series B Convertible Preferred Stock	(M)	4,870,244	1,991,443
			3,303,943
Questech Corporation (5)(6) -- Manufacturing and marketing proprietary metal and stone decorative tiles			
Common Stock	(M)	655,454	432,600
Solazyme, Inc. (5)(6)(7) -- Developing algal biodiesel, industrial chemicals and specialty ingredients based on synthetic biology			
Series A Convertible Preferred Stock	(M)	988,204	4,978,157
Series B Convertible Preferred Stock	(M)	495,246	2,494,841

Series C Convertible Preferred Stock	(M)	651,309	3,281,021 10,754,019
--------------------------------------	-----	---------	-------------------------

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
 CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
 (Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Non-Controlled Affiliated Companies (2)(13) – 33.4% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 33.4% of net assets at value (Cont.)			
Xradia, Inc. (5)(6) -- Designing, manufacturing and selling ultra-high resolution 3D x-ray microscopes and fluorescence imaging systems			
Series D Convertible Preferred Stock	(M)	3,121,099	\$ 6,323,658
Total Non-Controlled Private Placement Portfolio (cost: \$51,546,166)			
			\$ 45,559,645
Total Investments in Non-Controlled Affiliated Companies (cost: \$51,546,166)			
			\$ 45,559,645

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Controlled Affiliated Companies			
(2)(16) –			
5.6% of net assets at value			
Private Placement Portfolio (Illiquid) – 5.6% of net assets at value			
Ancora Pharmaceuticals Inc. (5)(6)(7) -- Developing synthetic carbohydrates for pharmaceutical applications			
Series B Convertible Preferred Stock	(M)	1,663,808	\$ 17,375
Series C Convertible Preferred Stock	(M)	2,066,051	1,239,631
Secured Convertible Bridge Note (including interest)	(M)	\$ 500,000	505,479
			1,762,485
Laser Light Engines, Inc. (5)(6)(7) -- Manufacturing solid-state light sources for digital cinema and large-venue projection displays			
Series A Convertible Preferred Stock	(M)	7,499,062	1,000,000
Secured Convertible Bridge Note (including interest)	(M)	\$ 1,640,000	1,712,278
			2,712,278
SiOnyx, Inc. (5)(6)(7)(17) -- Developing silicon-based optoelectronic products enabled by its proprietary "Black Silicon"			
Series A Convertible Preferred Stock	(M)	233,499	101,765
Series A-1 Convertible Preferred Stock	(M)	2,966,667	1,292,948
Series A-2 Convertible Preferred Stock	(M)	4,207,537	1,833,750
			3,228,463
Total Controlled Private Placement Portfolio (cost: \$11,032,574)			
		\$	7,703,226

Total Investments in Controlled Affiliated Companies (cost: \$11,032,574)	\$ 7,703,226
Total Private Placement and Publicly Traded Portfolio (cost: \$94,128,439)	\$ 83,567,400

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
 CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
 (Unaudited)

	Method of Valuation (1)	Shares/ Principal	Value
U.S. Government Securities (18) – 38.9% of net assets at value			
U.S. Treasury Bill -- due date 04/22/10	(M)	\$ 9,200,000	\$ 9,199,172
U.S. Treasury Bill -- due date 06/17/10	(M)	43,975,000	43,961,258
Total Investments in U.S. Government Securities (cost: \$53,163,696)			\$ 53,160,430
Total Investments (cost: \$147,292,135)			\$ 136,727,830

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

Notes to Consolidated Schedule of Investments

- (1) See Footnote to Consolidated Schedule of Investments on page 29 for a description of the Valuation Procedures.
- (2) Investments in unaffiliated companies consist of investments in which we own less than five percent of the voting shares of the portfolio company. Investments in non-controlled affiliated companies consist of investments in which we own five percent or more, but less than 25 percent, of the voting shares of the portfolio company, or where we hold one or more seats on the portfolio company's Board of Directors but do not control the company. Investments in controlled affiliated companies consist of investments in which we own 25 percent or more of the voting shares of the portfolio company or otherwise control the company.
- (3) The aggregate cost for federal income tax purposes of investments in unaffiliated private companies is \$31,002,395. The gross unrealized appreciation based on the tax cost for these securities is \$5,399,816. The gross unrealized depreciation based on the tax cost for these securities is \$6,650,136.
- (4) The aggregate cost for federal income tax purposes of investments in unaffiliated publicly traded companies is \$547,304. The gross unrealized appreciation based on the tax cost for these securities is \$5,797. The gross unrealized depreciation based on the tax cost for these securities is \$647.
- (5) We are subject to legal restrictions on the sale of this investment.
- (6) Represents a non-income producing security. Equity investments that have not paid dividends within the last 12 months are considered to be non-income producing.
- (7) These investments are development-stage companies. A development-stage company is defined as a company that is devoting substantially all of its efforts to establishing a new business, and either it has not yet commenced its planned principal operations, or it has commenced such operations but has not realized significant revenue from them.
- (8) With our purchase of Series E Convertible Preferred Stock of BioVex, we received a warrant to purchase a number of shares of common stock of BioVex as determined by dividing 624,999.99 by the price per share at which the common stock is offered and sold to the public in connection with the initial public offering ("IPO"). The ability to exercise this warrant is therefore contingent on BioVex completing successfully an IPO before the expiration date of the warrant on September 27, 2012. The exercise price of this warrant shall be 110 percent of the IPO price.
- (9) Cobalt Technologies, Inc., also does business as Cobalt Biofuels.

The accompanying notes are an integral part of this consolidated schedule.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF MARCH 31, 2010
(Unaudited)

- (10) D-Wave Systems, Inc., is located and is doing business primarily in Canada. We invested in D-Wave Systems, Inc., through D-Wave USA, a Delaware company. Our investment is denominated in Canadian dollars and is subject to foreign currency translation. See "Note 3. Summary of Significant Accounting Policies."
- (11) With our purchase of the Series B Convertible Preferred Stock of TetraVita Bioscience, Inc., we received the right to purchase, at a price of \$2.63038528 per share, a number of shares in the Series C financing equal to the number of shares of Series B Preferred Stock purchased. The ability to exercise this right is contingent on TetraVita Bioscience completing successfully a subsequent round of financing.
- (12) Initial investment was made during 2010.
- (13) The aggregate cost for federal income tax purposes of investments in non-controlled affiliated companies is \$51,546,166. The gross unrealized appreciation based on the tax cost for these securities is \$10,165,855. The gross unrealized depreciation based on the tax cost for these securities is \$16,152,376.
- (14) On February 28, 2008, Lifco, Inc., merged with CFX Battery, Inc. The surviving entity was CFX Battery, Inc. On February 24, 2010, CFX Battery, Inc., changed its name to Contour Energy Systems, Inc.
- (15) With our investment in a convertible bridge note issued by Ensemble Discovery, we received a warrant to purchase a number of shares of the class of stock sold in the next financing of Ensemble Discovery equal to \$149,539.57 divided by the price per share of the class of stock sold in the next financing of Ensemble Discovery. The ability to exercise this warrant is, therefore, contingent on Ensemble Discovery completing successfully a subsequent round of financing. This warrant shall expire and no longer be exercisable on September 10, 2015. The cost basis of this warrant is \$89.86.
- (16) The aggregate cost for federal income tax purposes of investments in controlled affiliated companies is \$11,032,574. The gross unrealized appreciation based on the tax cost for these securities is \$0. The gross unrealized depreciation based on the tax cost for these securities is \$3,329,348.
- (17) On February 23, 2010, the Company signed a contingent bridge note issued by SiOnyx, Inc., for \$339,760. These funds may be requested by the board of directors of SiOnyx on or before June 30, 2010. The funds were called by SiOnyx on April 22, 2010. We received a warrant to purchase a number of shares of the class of stock sold in the next financing of SiOnyx equal to \$169,880 divided by the price per share of the class of stock sold in the next financing. The ability to exercise this warrant and its expiration are, therefore, contingent on SiOnyx completing successfully a subsequent round of financing.
- (18) The aggregate cost for federal income tax purposes of our U.S. government securities is \$53,163,696. The gross unrealized appreciation on the tax cost for these securities is \$0. The gross unrealized depreciation on the tax cost of these securities is \$3,266.

The accompanying notes are an integral part of this consolidated schedule.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF DECEMBER 31, 2009

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 16.3% of net assets at value			
Private Placement Portfolio (Illiquid) – 16.1% of net assets at value			
BioVex Group, Inc. (5)(6)(7)(8) -- Developing novel biologics for treatment of cancer and infectious disease			
Series E Convertible Preferred Stock	(M)	2,799,552	\$ 1,042,862
Series G Convertible Preferred Stock	(M)	3,738,004	627,985
Warrants at \$0.21 expiring 11/5/16	(I)	285,427	20,836
			1,691,683
Cobalt Technologies, Inc. (5)(6)(7)(9) -- Developing processes for making biobutanol through biomass fermentation			
Series C Convertible Preferred Stock	(M)	352,112	375,000
D-Wave Systems, Inc. (5)(6)(7)(10) -- Developing high- performance quantum computing systems			
Series B Convertible Preferred Stock	(M)	1,144,869	907,612
Series C Convertible Preferred Stock	(M)	450,450	357,101
Series D Convertible Preferred Stock	(M)	1,533,395	1,215,622
			2,480,335
Molecular Imprints, Inc. (5)(6) -- Manufacturing nanoimprint lithography capital equipment			
Series B Convertible Preferred Stock	(M)	1,333,333	2,999,999
Series C Convertible Preferred Stock	(M)	1,250,000	2,812,500
Warrants at \$2.00 expiring 12/31/11	(I)	125,000	163,625
			5,976,124
Nanosys, Inc. (5)(6) -- Developing zero and one-dimensional inorganic nanometer-scale materials and devices			
Series C Convertible Preferred Stock	(M)	803,428	1,185,056

Series D Convertible Preferred Stock	(M)	1,016,950	1,500,001
			2,685,057

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF DECEMBER 31, 2009

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 16.3% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 16.1% of net assets at value (Cont.)			
Nantero, Inc. (5)(6)(7) -- Developing a high-density, nonvolatile, random access memory chip, enabled by carbon nanotubes			
Series A Convertible Preferred Stock	(M)	345,070	\$ 1,046,908
Series B Convertible Preferred Stock	(M)	207,051	628,172
Series C Convertible Preferred Stock	(M)	188,315	571,329
			2,246,409
NeoPhotonics Corporation (5)(6)(11) -- Developing and manufacturing optical devices and components			
Common Stock	(M)	1,100,013	739,209
Series 1 Convertible Preferred Stock	(M)	1,831,256	1,230,604
Series 2 Convertible Preferred Stock	(M)	741,898	498,555
Series 3 Convertible Preferred Stock	(M)	2,750,000	1,848,000
Series X Convertible Preferred Stock	(M)	8,923	1,427,680
Warrants at \$0.15 expiring 01/26/10	(I)	16,364	11,291
Warrants at \$0.15 expiring 12/05/10	(I)	14,063	9,703
			5,765,042
Polatis, Inc. (5)(6)(7) -- Developing MEMS-based optical networking components			
Series A-1 Convertible Preferred Stock	(M)	16,775	0
Series A-2 Convertible Preferred Stock	(M)	71,611	0
Series A-4 Convertible Preferred Stock	(M)	4,774	0
Series A-5 Convertible Preferred Stock	(M)	16,438	0
			0
PolyRemedy, Inc. (5)(6)(7) -- Developing a robotic			

manufacturing platform for wound treatment patches			
Series B-1 Convertible Preferred Stock	(M)	287,647	46,933
Series B-2 Convertible Preferred Stock	(M)	676,147	60,853
			107,786

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF DECEMBER 31, 2009

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Unaffiliated Companies (2)(3)(4) – 16.3% of net assets at value (Cont.)			
Private Placement Portfolio (Illiquid) – 16.1% of net assets at value (Cont.)			
Siluria Technologies, Inc. (5)(6)(7) -- Developing next-generation nanomaterials			
Series S-2 Convertible Preferred Stock	(M)	612,061	\$ 204,000
TetraVitae Bioscience, Inc. (5)(6)(7)(12) -- Developing methods of producing alternative chemicals and fuels through biomass fermentation			
Series B Convertible Preferred Stock	(M)	118,804	125,000
Total Unaffiliated Private Placement Portfolio (cost: \$26,977,200)			
			\$ 21,656,436
Publicly Traded Portfolio (Liquid) – 0.2% of net assets at value			
Orthovita, Inc. (6)(13) -- Developing materials and devices for orthopedic medical implant applications			
Common Stock	(M)	64,500	226,395

Total Unaffiliated Publicly Traded Portfolio (cost: \$298,827)	\$	226,395
Total Investments in Unaffiliated Companies (cost: \$27,276,027)	\$	21,882,831

The accompanying notes are an integral part of these consolidated financial statements.

HARRIS & HARRIS GROUP, INC.
 CONSOLIDATED SCHEDULE OF INVESTMENTS AS OF DECEMBER 31, 2009

	Method of Valuation (1)	Shares/ Principal	Value
Investments in Non-Controlled Affiliated Companies (2)(14) – 37.5% of net assets at value			
Private Placement Portfolio (Illiquid) – 37.5% of net assets at value			
Adesto Technologies Corporation (5)(6)(7) -- Developing low-power,			